Giulia Zamprogna

Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs

Candida Vitale, Chiara Salvetti, Valentina Griggio et al. · Blood · 2021 · 44 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +14

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Alessandra Tedeschi, Anna Maria Frustaci, Francesca Romana Mauro et al. · Blood Advances · 2021 · 30 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Duvelisib: A New Phosphoinositide-3-Kinase Inhibitor in Chronic Lymphocytic Leukemia

Anna Maria Frustaci, Alessandra Tedeschi, Marina Deodato et al. · Future Oncology · 2019 · 21 citations

Medicine, Oncology, Pharmacology +13

Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells

Alessandra Trojani, Barbara Di Camillo, Luca Emanuele Bossi et al. · Cancers · 2021 · 12 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome.

Anna Maria Frustaci, Marco Montillo, Davide Rossi et al. · Journal of Clinical Oncology · 2023 · 12 citations

Medicine, Hematology, Pharmacology +16